Stifel Downgrades Mirati Therapeutics (MRTX) to Hold

November 6, 2023 4:49 PM EST
Get Alerts MRTX Hot Sheet
Price: $58.70 --0%

Rating Summary:
    8 Buy, 18 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 14 | Down: 18 | New: 17
Join SI Premium – FREE

Stifel analyst Ben Burnett downgraded Mirati Therapeutics (NASDAQ: MRTX) from Buy to Hold with a price target of $59.00 (from $83.00).

For an analyst ratings summary and ratings history on Mirati Therapeutics click here. For more ratings news on Mirati Therapeutics click here.

Shares of Mirati Therapeutics closed at $56.02 yesterday.

You May Also Be Interested In

Related Categories

Analyst PT Change, Downgrades